IRIS
FRANCHINA, Tindara
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 5.773
NA - Nord America 4.399
AS - Asia 2.508
SA - Sud America 831
AF - Africa 79
Continente sconosciuto - Info sul continente non disponibili 8
OC - Oceania 4
Totale 13.602
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.290
RU - Federazione Russa 2.950
SG - Singapore 1.033
CN - Cina 712
BR - Brasile 707
SE - Svezia 605
IE - Irlanda 585
IT - Italia 345
PL - Polonia 302
FR - Francia 295
HK - Hong Kong 276
DE - Germania 179
VN - Vietnam 142
UA - Ucraina 121
GB - Regno Unito 113
FI - Finlandia 102
IN - India 85
CA - Canada 48
AT - Austria 46
BD - Bangladesh 44
AR - Argentina 42
BE - Belgio 33
MX - Messico 32
IQ - Iraq 28
ZA - Sudafrica 28
ID - Indonesia 27
UZ - Uzbekistan 24
EC - Ecuador 23
TR - Turchia 22
NL - Olanda 19
CO - Colombia 18
JP - Giappone 15
PK - Pakistan 14
VE - Venezuela 14
ES - Italia 13
PH - Filippine 13
CZ - Repubblica Ceca 11
NP - Nepal 11
JM - Giamaica 10
MA - Marocco 10
CL - Cile 9
AL - Albania 8
EE - Estonia 8
SA - Arabia Saudita 8
LT - Lituania 7
TN - Tunisia 7
AE - Emirati Arabi Uniti 6
CI - Costa d'Avorio 6
DZ - Algeria 6
EG - Egitto 6
EU - Europa 6
KE - Kenya 6
JO - Giordania 5
PY - Paraguay 5
UY - Uruguay 5
BG - Bulgaria 4
BO - Bolivia 4
DO - Repubblica Dominicana 4
KG - Kirghizistan 4
KZ - Kazakistan 4
LK - Sri Lanka 4
MY - Malesia 4
RO - Romania 4
CH - Svizzera 3
CR - Costa Rica 3
HR - Croazia 3
IR - Iran 3
PA - Panama 3
PE - Perù 3
RS - Serbia 3
SY - Repubblica araba siriana 3
AO - Angola 2
AU - Australia 2
AZ - Azerbaigian 2
GA - Gabon 2
GE - Georgia 2
GT - Guatemala 2
IL - Israele 2
LB - Libano 2
LV - Lettonia 2
MD - Moldavia 2
NG - Nigeria 2
NI - Nicaragua 2
NO - Norvegia 2
OM - Oman 2
PS - Palestinian Territory 2
SK - Slovacchia (Repubblica Slovacca) 2
TH - Thailandia 2
TT - Trinidad e Tobago 2
XK - ???statistics.table.value.countryCode.XK??? 2
AM - Armenia 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BH - Bahrain 1
BN - Brunei Darussalam 1
BY - Bielorussia 1
CG - Congo 1
DK - Danimarca 1
ET - Etiopia 1
GR - Grecia 1
Totale 13.589
Salva come PNG Salva come JPEG
Città #
Moscow 840
Ashburn 697
Dublin 583
Singapore 542
Chandler 489
Dallas 411
Nyköping 294
Warsaw 291
Hong Kong 276
Jacksonville 243
Beijing 240
San Jose 217
New York 137
The Dalles 137
Messina 127
Los Angeles 115
Ann Arbor 97
Dearborn 93
Princeton 93
Lauterbourg 83
Medford 82
Cambridge 74
Des Moines 70
São Paulo 55
Buffalo 47
Ho Chi Minh City 45
Munich 44
Boardman 41
Vienna 39
Tianjin 37
Woodbridge 36
Brussels 33
Council Bluffs 32
Frankfurt am Main 28
Pune 28
Dong Ket 24
Orem 23
San Mateo 23
Wilmington 23
Jinan 22
Shenyang 21
Tashkent 21
Hanoi 20
Redondo Beach 20
Santa Clara 20
Belo Horizonte 18
Guangzhou 18
Jakarta 18
Turku 18
Chennai 17
Lancaster 17
Montreal 17
Stockholm 17
Johannesburg 16
London 16
Nanjing 16
Rio de Janeiro 16
Chicago 15
Helsinki 15
Atlanta 14
Brasília 14
Brooklyn 14
Fort Washington 14
Grammichele 14
Houston 14
San Francisco 14
Tokyo 13
Amsterdam 12
Boston 12
Curitiba 12
Denver 12
Hebei 12
Shanghai 12
Manchester 11
Quito 11
Mexico City 10
Nuremberg 10
Porto Alegre 10
Rome 10
Taizhou 10
Campinas 9
Milan 9
Mumbai 9
Paternò 9
Seattle 9
Shenzhen 9
Toronto 9
Zhengzhou 9
Baghdad 8
Duque de Caxias 8
Düsseldorf 8
Hangzhou 8
Leawood 8
Phoenix 8
Caracas 7
Dhaka 7
Goiânia 7
Hyderabad 7
Istanbul 7
Jiaxing 7
Totale 7.564
Salva come PNG Salva come JPEG
Nome #
A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): old successes and future perspectives 242
Prognostic value of methlylenetetrahydrofolate reductase (MTHFR), thymidylate synthase (TS) promoter, and p53 codon 72 variants and survival in advanced non-small cell lung cancer (NSCLC). 234
Activity of pegylated liposomal doxorubicin in combination with gemcitabine in triple negative breast cancer with skin involvement: Two case reports. 217
Androgen Receptor (AR), E-Cadherin, and Ki-67 as emerging targets and novel prognostic markers in triple-negative breast cancer (TNBC) patients 217
Androgen receptor (AR), E-cadherin, and Ki-67 as prognostic markers in triple-negative breast cancer (TNBC). 211
Baseline neutrophilia, derived neutrophil-to-lymphocyte ratio (dNLR), platelet-to-lymphocyte ratio (PLR), and outcome in non small cell lung cancer (NSCLC) treated with Nivolumab or Docetaxel 204
The prognostic significance of combined androgen receptor, E-Cadherin, Ki67 and CK5/6 expression in patients with triple negative breast cancer 199
Impact of integrated treatments on patient management in solid tumors: from diagnosis to palliative care. 196
Activity and safety of gefitinib and erlotinib in metastatic non-small cell lung cancer (NSCLC): A comparative analysis. 193
Folate pathway implications in advanced Non Small Cell Lung Cancer (NSCLC): impact of thymidylate synthase (TS) promoter and methlylenetetrahydrofolate reductase (MTHFR) C677T and A1298C variants expression on patients’ outcome and correlation with p53 codon 72 mutations. 191
Efficacy of nab-paclitaxel plus trastuzumab in a long-surviving heavily pretreated HER2-positive breast cancer patient with brain metastases 184
Heterogeneous responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with uncommon EGFR mutations: New insights and future perspectives in this complex clinical scenario 184
Emerging role of Radium-223 in the growing therapeutic armamentarium of metastatic castration-resistant prostate cancer 179
Vaginal Mucosal Melanoma: a Complete Remission after Immunotherapy and '0-7-21' Radiotherapy Regimen (24 Gy/3 fractions/21 days) 174
A new method for titration of oral transmucosal fentanyl citrate (OTFC) starting dose in cancer patients. 173
Circulating miR-22, miR-24 and miR-34a as novel predictive biomarkers to pemetrexed-based chemotherapy in advanced non small cell lung cancer. 173
Can we better manage advanced NSCLC in the elderly with the new therapeutic agents? Preliminary analysis of a real life multicenter study. 173
Brain metastases in patients with non-small cell lung cancer: focus on the role of chemotherapy. 171
Clinical significance of circulating interleukin-23 as a prognostic factor in breast cancer patients. 171
Central nervous system involvement in ALK-rearranged NSCLC: promising strategies to overcome crizotinib resistance 171
Gefitinib versus Erlotinib treatment in Non Small Cell Lung Cancer (NSCLC): comparison of two clinical experiences. 166
Second-line therapy in advanced non-small cell lung cancer: Cytotoxic agents or tyrosine kinase inhibitors? Our experience. 165
The palliative role of Gefitinib (Iressa) in the treatment of heavily pretreated patients with advanced, refractory non small cell lung cancer. Results of a 3-year experience. 164
Epidermal growth factor receptor (EGFR) G719C mutation as new determinant of long term survival and response in patients with non small cell lung cancer treated with erlotinib: 164
Efficacy of T-DM1 for leptomeningeal and brain metastases in a HER2 positive metastatic breast cancer patient: New directions for systemic therapy - a case report and literature review 164
Is the adenocarcinoma subtype a predictor of response to Pemetrexed in patients with non small cell lung cancer? Our preliminary data 163
Correction: Androgen Receptor (AR), E-cadherin, and Ki-67 as emerging targets and novel prognostic markers in Triple-Negative Breast Cancer (TNBC) patients 161
Author Correction to: Prevalence of Use and Cost of Biological Drugs for Cancer Treatment: A 5-Year Picture from Southern Italy 159
Is the adenocarcinoma subtype a predictor of response to Pemetrexed in patients with non small cell lung cancer? Our preliminary data. 158
Induction chemotherapy with paclitaxel and cisplatin to concurrent radiotherapy and weekly paclitaxel in the treatment of loco-regionally advanced, stage IV (M0), head and neck squamous cell carcinoma. Mature results of a prospective study. 155
Influence of EGFR mutational status on metastatic behavior in non squamous non small cell lung cancer 154
Nab-paclitaxel and trastuzumab combination: A promising approach for neoadjuvant treatment in HER2-positive breast cancer 154
Challenges and promises of physical exercise in advances lung cancer patients 152
Adverse Drug Reactions with HER2-Positive Breast Cancer Treatment: An Analysis from the Italian Pharmacovigilance Database 152
Impact of integrated treatments on patient management in solid tumors: From diagnosis to palliative care. 148
Predicting sensitivity of non small cell lung cancer to gefitinib and erlotinib: is there still a role for clinical factors ? 148
Third generation EGFR TKIs in EGFR-mutated NSCLC: Where are we now and where are we going 147
Embolia polmonare 146
Impact of erlotinib on overall survival in non small cell lung cancer patients: is the post progression survival a new paradigm? 146
Role of Androgen Receptor (AR), Ki 67 and E-cadherin as prognostic markers in Triple Negative Breast Cancer (TNBC) 146
The changing scenario of 1st line therapy in non-oncogene addicted NSCLCs in the era of immunotherapy 145
IL-33/IL-31 axis: A new pathological mechanism for epidermal growth factor receptor tyrosine kinase inhibitors-associated skin toxicity? 145
Incidence and preferential localizations of bone metastases: biomolecolar and clinical implications. 142
Epidermal growth factor receptor (EGFR) G719C mutation as new determinant of long term survival and response in patients with non small cell lung cancer treated with erlotinib: a case report. 142
Long time response with chemotherapy in ROS1 NSCLC patient with unusual metastatic site 140
Impact of single-nucleotide polymorphisms in genes coding for folate pathway enzymes on efficacy/toxicity of gemcitabine and pemetrexed based therapy in advanced non small cell lung cancer (NSCLC): new prospectives for old markers. 139
Emerging targeted therapies for castration-resistant prostate cancer 138
Pegylated liposomal doxorubicin in combination with gemcitabine in elderly women with locally advanced or metastatic breast cancer: safety and activity results of our clinical experience. 136
Impact of circulating microRNAs mir-22, mir-24 and mir-34a on response to pemetrexed in patients with non small cell lung cancer 135
Corticosteroids in oncology: Use, overuse, indications, contraindications. An Italian Association of Medical Oncology (AIOM)/ Italian Association of Medical Diabetologists (AMD)/ Italian Society of Endocrinology (SIE)/ Italian Society of Pharmacology (SIF) multidisciplinary consensus position paper 131
NSCLC and HER2: between lights and shadows 131
Safety and activity of trastuzumab-containing therapies for the treatment of metastatic breast cancer: our long-term clinical experience (GOIM study) 130
The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR status 129
Ruolo del Trastuzumab nel Trattamento Adiuvante del Carcinoma Mammario Operabile. 127
Benefits and Harms of Lung Cancer Screening by Chest Computed Tomography: A Systematic Review and Meta-Analysis 125
May the istotype influence the response to pemetrexed in patients with non small cell lung cancer? Preliminary data of our clinical experience. 124
New biomarkers to predict response to pemetrexed-based chemotherapy in non small cell lung cancer: from 5,10-methylenetetrahydrofolate reductase promises to miRNAs revolution. 123
Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter Study 123
Management of Endocrine and Metabolic Toxicities of Immune-Checkpoint Inhibitors: From Clinical Studies to a Real-Life Scenario 121
Rapid Acquisition of T790M Mutation after Treatment with Afatinib in an NSCLC Patient Harboring EGFR Exon 20 S768I Mutation 121
SAFETY AND ACTIVITY OF ERLOTINIB (TARCEVA) IN HEAVILY PRE-TREATED PATIENTS WITH METASTATIC, REFRACTORY NON SMALL CELL LUNG CANCER 120
Molecular and clinical analysis of predictive biomarkers to anti-EGFR inhibitors in metastatic colorectal cancer (mCRC): Interaction among early tumor shrinkage, skin toxicities, and RAS status. 119
Diagnosis and treatment of early and locally advanced non-small-cell lung cancer: The 2019 AIOM (Italian Association of Medical Oncology) clinical practice guidelines 118
Safety of trastuzumab, alone or in combination, in elderly patients with HER2-positive breast cancer: A 5-year case series. 114
Safety profile of tyrosine kinase inhibitors used in non-small-cell lung cancer: An analysis from the Italian pharmacovigilance database 113
Gefitinib in lung cancer therapy. Clinical results, predictive markers of response and future perspectives. 113
Ruolo del Trastuzumab nel Trattamento Adiuvante del Carcinoma Mammario Operabile 112
Neoplasie della testa collo nell’ anziano 109
Ruolo di Trastuzumab nella terapia adiuvante del carcinoma mammario operabile. 108
Role of interleukin-23 circulating levels increase in resected colorectal cancer before and after chemotherapy: preliminary data and future perspectives. 108
Rare histotypes of epithelial biliary tract tumors: A literature review 107
Safety of the combination Capecitabine plus Bevacizumab in the treatment of heavily treated advanced colorectal cancer patients: Our experience. 105
Neuropsychiatric adverse drug reactions with oral tyrosine kinase inhibitors in metastatic colorectal cancer: an analysis from the FDA Adverse Event Reporting System 104
Role of MTHFR polymorphisms as predictive markers of acute toxicity during 5-fluorouracil based chemotherapy for colorectal cancer: Preliminary data. 103
Turbe della nutrizione: anoressia e cachessia. 103
Safety and clinical activity of trastuzumab (TSM) containing therapies in heavily pretreated patients with metastatic breast cancer (MBC): A five-year experience 99
Listening understanding and acting (lung): Focus on communicational issue in thoracic oncology 98
Treatment of advanced non-small-cell lung cancer: The 2019 AIOM (Italian Association of Medical Oncology) clinical practice guidelines 97
Neuropsychiatric Adverse Drug Reactions with Tyrosine Kinase Inhibitors in Gastrointestinal Stromal Tumors: An Analysis from the European Spontaneous Adverse Event Reporting System 96
Molecular profiling in Italian patients with advanced non-small-cell lung cancer: An observational prospective study 93
Neoplasie della Testa e del Collo nell'anziano 90
POLIMORPHISM OF METHYLENE-TETRAHYDROFOLATE REDUCTASE AND RISK OF LUNG AND COLON-RECTAL CANCER: A CASE CONTROL STUDY 90
Temozolamide plus oral vinorelbine in the treatment of brain metastases from solid tumours in heavily pre- treated patients. 89
Immune Checkpoint Inhibitors and the Kidney: A Focus on Diagnosis and Management for Personalised Medicine 88
Safety and activity of trastuzumab (TRA) containing therapies as treatment of metastatic breast cancer(MBC): a five year experience. 86
“Lunga stazionarietà di malattia e clinical benefit con erlotinib in un paziente anziano, forte fumatore, affetto da carcinoma squamoso del polmone”. 86
Invecchiamento e cancro. 84
Quality of life analysis of TORCH, a randomized trial testing first-line erlotinib followed by second-line cisplatin/gemcitabine chemotherapy in advanced non-small-cell lung cancer. 82
Use of nivolumab in elderly patients with advanced Non-Squamous NSCLC: results from the Italian Expanded Access Program (EAP) 82
Cardiotoxicity Induced by Anticancer Therapies: A Call for Integrated Cardio-Oncology Practice 80
Is multidisciplinary management possible in the treatment of lung cancer? A report from three Italian meetings 80
Renal Disorders with Oral Tyrosine Kinase Inhibitors in Metastatic Colorectal Cancer: An Analysis from the FDA Adverse Event Reporting System Database 75
Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab 75
Treatment option for small cell lung cancer: does lanreotide represent a new choice? 74
FGFR a promising druggable target in cancer: Molecular biology and new drugs 73
Re-treatment with gefitinib or treatment with erlotinib after gefitinib failure in responsive non small cell lung cancers: new strategies to overcome acquired resistance. 72
Prediction and validation of GUCA2B as the hub-gene in colorectal cancer based on co-expression network analysis: In-silico and in-vivo study 71
Negative Hyperselection in Metastatic Colorectal Cancer for First-Line Anti-EGFR Therapy: A Narrative Review 69
Unveiling cardiovascular and respiratory toxicities with monoclonal antibodies in multiple myeloma: disproportionality analysis from the FDA Adverse Event Reporting System 68
Neuropsychiatric Adverse Events with Monoclonal Antibodies Approved for Multiple Myeloma: An Analysis from the FDA Adverse Event Reporting System 65
Totale 13.334
Salva come PNG Salva come JPEG
Categoria #
all - tutte 43.473
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 43.473
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202149 0 0 0 0 0 0 0 0 0 0 0 49
2021/2022668 6 71 23 19 28 7 29 27 5 163 90 200
2022/20231.841 128 179 74 157 136 184 49 129 724 9 49 23
2023/2024495 25 80 32 29 23 175 60 4 2 21 8 36
2024/20252.055 34 22 34 112 104 82 57 451 473 156 192 338
2025/20266.676 332 378 474 431 551 1.403 862 914 824 293 110 104
Totale 13.797